Arleen Rifkind received a B.A. degree from Bryn Mawr College and M.D. degree from NYU Medical School. After residency training in internal medicine at Bellevue Hospital in NYC, she spent three years at the NIH as a Clinical Associate (Endocrine Division of the Cancer Institute) where she participated in the discovery that gonadotropins are secreted substantially before puberty. A Research Associateship at Rockefeller University introduced her to her long-term research interests: heme biosynthesis, cytochrome P450, drug metabolism, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD/dioxin) toxicity. She joined Weill/Cornell Medical School where she has been Professor of Pharmacology since 1983. She served on or led several NIH study sections including the Toxicology Study Section and is currently a member of the advisory board of the Wayne State University (Environmental Health Sciences Center). She has been an Associate Editor of Drug Metabolism and Disposition and has served on editorial boards of Biochemical Pharmacology and Toxicology and Applied Pharmacology. Her research and publications have focused on mechanisms of aryl hydrocarbon receptor (AhR) mediated toxicity, roles of cytochrome P4501A induction and mitochondria in TCDD effects, and production of AhR activators by light. She pioneered use of the chick embryo as a model for TCDD toxicity studies. Her group cloned and sequenced the avian CYP1A enzymes, CYPs1A4 and 1A5 and discovered that human CYP1A2 and chick CYP1A5 are highly active arachidonic acid epoxygenases. Her laboratory is currently studying transcriptional and posttranscriptional effects of AhR activation and CYP1A induction leading to dysregulation of signaling pathways governing nutrient and energy metabolism.
Biography Updated on 11 February 2008